Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

XOMA Royalty Corporation - Common Stock (NQ:XOMA)

33.31 -0.04 (-0.10%)
Streaming Delayed Price Updated: 11:05 AM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,593
Open 33.21
Bid (Size) 32.98 (2)
Ask (Size) 33.75 (1)
Prev. Close 33.35
Today's Range 32.55 - 33.59
52wk Range 18.35 - 39.92
Shares Outstanding 11,782,723
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
From Mural Oncology plc
Via GlobeNewswire
LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty
As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon. 
Via Stocktwits

Performance

YTD
+28.1%
+28.1%
1 Month
-10.4%
-10.4%
3 Month
+29.9%
+29.9%
6 Month
+38.6%
+38.6%
1 Year
+4.3%
+4.3%

More News

Read More
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting
Via Stocktwits
Mural Oncology To Be Acquired By Xoma Royalty
Via Stocktwits
XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality
Via MarketMinute
Topics Intellectual Property Workforce
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
From XOMA Royalty Corporation; LAVA Therapeutics
Via GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
From XOMA Royalty Corporation
Via GlobeNewswire
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
From XOMA Royalty Corporation
Via GlobeNewswire
HILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX
From Kahn Swick & Foti, LLC
Via GlobeNewswire
XOMA Revenue Jumps 39% in Fiscal Q2
Via The Motley Fool
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
From XOMA Royalty Corporation
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
From Brodsky & Smith LLC
Via GlobeNewswire
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
From XOMA Royalty Corporation
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)
From Brodsky & Smith LLC
Via GlobeNewswire
Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps
Via Stocktwits
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
From XOMA Royalty Corporation; Turnstone Biologics Corp.
Via GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
From XOMA Royalty Corporation; BioInvent
Via GlobeNewswire
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire

Frequently Asked Questions

Is XOMA Royalty Corporation - Common Stock publicly traded?
Yes, XOMA Royalty Corporation - Common Stock is publicly traded.
What exchange does XOMA Royalty Corporation - Common Stock trade on?
XOMA Royalty Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for XOMA Royalty Corporation - Common Stock?
The ticker symbol for XOMA Royalty Corporation - Common Stock is XOMA on the Nasdaq Stock Market
What is the current price of XOMA Royalty Corporation - Common Stock?
The current price of XOMA Royalty Corporation - Common Stock is 33.31
When was XOMA Royalty Corporation - Common Stock last traded?
The last trade of XOMA Royalty Corporation - Common Stock was at 10/30/25 11:05 AM ET
What is the market capitalization of XOMA Royalty Corporation - Common Stock?
The market capitalization of XOMA Royalty Corporation - Common Stock is 392.54M
How many shares of XOMA Royalty Corporation - Common Stock are outstanding?
XOMA Royalty Corporation - Common Stock has 393M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.